Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to be announcing its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $0.27 per share for the quarter.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. The company’s revenue was up 41.5% on a year-over-year basis. On average, analysts expect Supernus Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of Supernus Pharmaceuticals (SUPN) opened at $39.40 on Friday. Supernus Pharmaceuticals has a 12-month low of $24.92 and a 12-month high of $50.04. The firm has a market capitalization of $2,070.00, a PE ratio of 35.82 and a beta of 1.08.
In other news, VP Victor Vaughn sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total value of $630,600.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares in the company, valued at $1,023,421.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 165,750 shares of company stock valued at $7,133,973. Corporate insiders own 6.70% of the company’s stock.
A number of equities research analysts recently weighed in on SUPN shares. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 price objective on the stock in a research report on Wednesday, November 8th. ValuEngine downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. B. Riley raised their price objective on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, December 28th. Finally, Piper Jaffray Companies set a $41.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, October 29th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $51.36.
COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Monday” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/25/supernus-pharmaceuticals-supn-to-release-quarterly-earnings-on-monday.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.